AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29974494 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Number of subjects: 0
Study 29974494 — intervention group
Group type: COMPARATOR
Intervention: DBPCFC
Number of subjects: 0
Study 27191693 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent training (15-20 minutes of aerobic exercise plus 40 minutes of resistance exercise), 3 times per week, for 16 weeks.
Number of subjects: 33
Study 27191693 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent training
Number of subjects: 33
Study 27191693 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 33
Study 24354547 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention as part of a National Institute on Drug Abuse‐funded clinical trial of a screening and brief intervention protocol
Number of subjects: 147
Study 22692651 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet based, nurse led vascular risk factor management programme promoting self management for 12 months.
Number of subjects: 330
Study 22692651 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone.
Number of subjects: 330
Study 21096475 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-based motor imagery brain-computer interface (MI-BCI) with robotic feedback neurorehabilitation
Number of subjects: 54
Study 21096475 — intervention group
Group type: COMPARATOR
Intervention: Robotic rehabilitation that delivers movement therapy
Number of subjects: 54
Study 18407881 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 312
Study 18407881 — intervention group
Group type: COMPARATOR
Intervention: Vocational Services
Number of subjects: 312
Study 16022078 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus total mesorectal excision (TME)
Number of subjects: 1302
Study 16022078 — intervention group
Group type: COMPARATOR
Intervention: TME only
Number of subjects: 1302
Study 12052800 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily elemental zinc (10 mg for infants, 20 mg for older children)
Number of subjects: 2482
Study 12052800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2482
Study 10607811 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 900
Study 9180409 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrosystem (topical surfactant)
Number of subjects: 50
Study 9180409 — intervention group
Group type: COMPARATOR
Intervention: Untreated side (control)
Number of subjects: 50
Study 1860291 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal/Bicarbonate Toothpaste
Number of subjects: 0
Study 1860291 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride Toothpaste
Number of subjects: 0
Study 1860291 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 0
Study 6350475 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (ACV)
Number of subjects: 0
Study 6350475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30801889 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginoscopy
Number of subjects: 1597
Study 30801889 — intervention group
Group type: COMPARATOR
Intervention: Standard Hysteroscopy
Number of subjects: 1597
Study 28732435 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levamisole (50 mg twice a day for two weeks with each vaccination)
Number of subjects: 217
Study 28732435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 25806661 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard DBT
Number of subjects: 99
Study 25806661 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT-S
Number of subjects: 99
Study 25806661 — intervention group
Group type: COMPARATOR
Intervention: DBT-I
Number of subjects: 99
Study 24821457 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoic acid (1,200 mg/day)
Number of subjects: 52
Study 24821457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 22292370 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 200
Study 22292370 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolaminum
Number of subjects: 200
Study 22292370 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisodamine
Number of subjects: 200
Study 22292370 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine nursing treatment)
Number of subjects: 200
Study 19207720 — intervention group
Group type: EXPERIMENTAL
Intervention: MI + perindopril + losartan
Number of subjects: 0
Study 19207720 — intervention group
Group type: COMPARATOR
Intervention: MI + perindopril
Number of subjects: 0
Study 19207720 — intervention group
Group type: COMPARATOR
Intervention: MI + losartan
Number of subjects: 0
Study 17259403 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 3534
Study 17259403 — intervention group
Group type: EXPERIMENTAL
Intervention: KCNJ11 E23K variant
Number of subjects: 3534
Study 17259403 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCC8 A1369S variant
Number of subjects: 3534
Study 15238983 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led early discharge
Number of subjects: 108
Study 15238983 — intervention group
Group type: COMPARATOR
Intervention: Conventional stay
Number of subjects: 108
Study 11593938 — intervention group
Group type: EXPERIMENTAL
Intervention: High emotional intensity condition
Number of subjects: 170
Study 11593938 — intervention group
Group type: COMPARATOR
Intervention: Low emotional intensity condition
Number of subjects: 170
Study 11593938 — intervention group
Group type: EXPERIMENTAL
Intervention: Valence properties varied condition
Number of subjects: 170
Study 11593938 — intervention group
Group type: COMPARATOR
Intervention: Affective qualities matched condition
Number of subjects: 170
Study 9483341 — intervention group
Group type: EXPERIMENTAL
Intervention: In-room calendars (n = 14)
Number of subjects: 30
Study 9483341 — intervention group
Group type: COMPARATOR
Intervention: No calendars (n = 16)
Number of subjects: 30
Study 8034816 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral mood management intervention (10 group sessions over 8 weeks)
Number of subjects: 149
Study 8034816 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (5 group sessions over 8 weeks)
Number of subjects: 149
Study 8034816 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 149
Study 2589581 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program (Group 1, 103 patients, 203 limbs)
Number of subjects: 203
Study 2589581 — intervention group
Group type: COMPARATOR
Intervention: No education (Group 2, 100 patients, 193 limbs)
Number of subjects: 203
Study 2589581 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program (Group 1)
Number of subjects: 203
Study 2589581 — intervention group
Group type: COMPARATOR
Intervention: No education (Group 2)
Number of subjects: 203
Study 30099400 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic manual ventilation using a bag-valve-mask device
Number of subjects: 400
Study 30099400 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic ventilation
Number of subjects: 400
Study 26535872 — intervention group
Group type: EXPERIMENTAL
Intervention: 150,000 IU vitamin D3
Number of subjects: 22
Study 26535872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 25505257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 3883
Study 25505257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3883
Study 23290128 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported dizziness
Number of subjects: 391
Study 23290128 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 391
Study 23290128 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived fatigue
Number of subjects: 391
Study 23290128 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurring falls
Number of subjects: 391
Study 23290128 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive drowsiness
Number of subjects: 391
Study 23290128 — intervention group
Group type: EXPERIMENTAL
Intervention: Final model discrimination
Number of subjects: 391
Study 20051714 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (10(‐5) mol/l)
Number of subjects: 0
Study 20051714 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0
Study 20051714 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (10(‐6) mol/l)
Number of subjects: 0
Study 20051714 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 20051714 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 18652840 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print-based intervention
Number of subjects: 85
Study 18652840 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 85
Study 16109077 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg oral ascorbic acid 3x/week for 8 weeks (n=10)
Number of subjects: 153
Study 16109077 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg intravenous ascorbic acid 3x/week for 8 weeks (n=11)
Number of subjects: 153
Study 16109077 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral ascorbic acid 3x/week for 3 months (n=70)
Number of subjects: 153
Study 16109077 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n=83)
Number of subjects: 153
Study 12374323 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditionals of the form If A then C and If A then possibly C
Number of subjects: 0
Study 10425594 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of ondansetron
Number of subjects: 100
Study 10425594 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg of dimenhydrinate
Number of subjects: 100
Study 10425594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11837089 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular implant-retained overdentures
Number of subjects: 3
Study 11837089 — intervention group
Group type: COMPARATOR
Intervention: Conventional mandibular denture (mucosa-borne)
Number of subjects: 3
Study 11837089 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular overdenture retained by two IMZ-implants (implant-mucosa-borne)
Number of subjects: 3
Study 11837089 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular overdenture on a transmandibular implant (TMI; mainly implant-borne)
Number of subjects: 3
Study 2255749 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (20 mg)
Number of subjects: 18
Study 2255749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6452987 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclocycline sulfosalicylate cream, 1 percent, applied twice daily
Number of subjects: 351
Study 6452987 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclocycline sulfosalicylate cream, 1 percent
Number of subjects: 351
Study 31021451 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-free digital workflow using digital impressions immediately after implant placement
Number of subjects: 40
Study 31021451 — intervention group
Group type: COMPARATOR
Intervention: Hybrid workflow using conventional impressions
Number of subjects: 40
Study 31021451 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-free digital workflow
Number of subjects: 40
Study 28339999 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate
Number of subjects: 120
Study 28339999 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 120
Study 25595417 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 8888
Study 25595417 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20-40 mg/day
Number of subjects: 8888
Study 25595417 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 8888
Study 25595417 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 8888
Study 23343690 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Radial Access (LRA)
Number of subjects: 413
Study 23343690 — intervention group
Group type: COMPARATOR
Intervention: Right Radial Access (RRA)
Number of subjects: 413
Study 21118309 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (initial dose, 15 mg per week)
Number of subjects: 37
Study 21118309 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (initial dose, 5 mg per kg of bodyweight per day)
Number of subjects: 37
Study 21118309 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 37
Study 21118309 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 37
Study 19117328 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist supervised training group
Number of subjects: 61
Study 19117328 — intervention group
Group type: COMPARATOR
Intervention: Self‐directed training group
Number of subjects: 61
Study 19117328 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study 18326780 — intervention group
Group type: EXPERIMENTAL
Intervention: Audience Response System (ARS)
Number of subjects: 0
Study 18326780 — intervention group
Group type: COMPARATOR
Intervention: Survey on ARS use
Number of subjects: 0
Study 15336614 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 25
Study 15336614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 12082657 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 4,000 to 10,000 IU by subcutaneous injection 3 times weekly
Number of subjects: 108
Study 12082657 — intervention group
Group type: COMPARATOR
Intervention: Oral indomethacin 50 mg twice daily (Control group)
Number of subjects: 108
Study 9681078 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg once daily
Number of subjects: 555
Study 9681078 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 0.5 mg once daily
Number of subjects: 555
Study 9681078 — intervention group
Group type: COMPARATOR
Intervention: Aminoglutethimide 250 mg twice daily
Number of subjects: 555
Study 8006395 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (0.6 to 0.3 mg/kg per day for 1 month) followed by interferon alfa‐2a (3 MU/m2, thrice weekly, for 12 months)
Number of subjects: 43
Study 8006395 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 43
Study 2456731 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil with folate supplements
Number of subjects: 0
Study 2456731 — intervention group
Group type: EXPERIMENTAL
Intervention: Maloprim with folate supplements
Number of subjects: 0
Study 2456731 — intervention group
Group type: COMPARATOR
Intervention: Chlorproguanil without folate supplements
Number of subjects: 0
Study 2456731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29668608 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg (group D1)
Number of subjects: 100
Study 29668608 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.5 μg/kg (group D2)
Number of subjects: 100
Study 29668608 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 μg/kg (group D3)
Number of subjects: 100
Study 29668608 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group R)
Number of subjects: 100
Study 29133488 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders for influenza vaccination
Number of subjects: 6177
Study 29133488 — intervention group
Group type: COMPARATOR
Intervention: No SMS reminders (control)
Number of subjects: 6177
Study 29133488 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders for children younger than 5 years
Number of subjects: 6177
Study 26262276 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D CPR game
Number of subjects: 97
Study 26262276 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study 23438411 — intervention group
Group type: EXPERIMENTAL
Intervention: Forgiveness intervention
Number of subjects: 78
Study 23438411 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 78
Study 21307769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine (5, 6, 7, 8, 9, 10, or 11 mg) coadministered with 200 μg morphine and 10 μg fentanyl
Number of subjects: 42
Study 21307769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine (low doses)
Number of subjects: 42
Study 21307769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine
Number of subjects: 42
Study 19190211 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine 0.58 mg/kg/d
Number of subjects: 112
Study 19190211 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine 0.83 mg/kg/d
Number of subjects: 112
Study 19190211 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine 1.17 mg/kg/d
Number of subjects: 112
Study 16794504 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 courses of chemotherapy (nitrogen mustard, oncovin, prednisone, procarbazine/doxorubicin, bleomycin, vinblastine, dacarbazine)
Number of subjects: 0
Study 16794504 — intervention group
Group type: COMPARATOR
Intervention: 4 courses of chemotherapy (nitrogen mustard, oncovin, prednisone, procarbazine/doxorubicin, bleomycin, vinblastine, dacarbazine) + 2550 cGy involved‐field radiotherapy
Number of subjects: 0
Study 16794504 — intervention group
Group type: EXPERIMENTAL
Intervention: Early complete response
Number of subjects: 0
Study 16794504 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and chemoradiotherapy
Number of subjects: 0
Study 12759862 — intervention group
Group type: EXPERIMENTAL
Intervention: DCR with excision of the posterior sac mucosal flap (Group B)
Number of subjects: 80
Study 12759862 — intervention group
Group type: COMPARATOR
Intervention: DCR without excision of the posterior sac mucosal flap (Group A)
Number of subjects: 80
Study 11938825 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenlong Oral Liquid (SLOL) combined with radiotherapy
Number of subjects: 60
Study 9506009 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational transdermal testosterone systems
Number of subjects: 19
Study 8402806 — intervention group
Group type: EXPERIMENTAL
Intervention: Single application of 40% chlorhexidine varnish
Number of subjects: 29
Study 8402806 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated application of 40% chlorhexidine varnish (two applications)
Number of subjects: 29
Study 8402806 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish (control group)
Number of subjects: 29
Study 3618133 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline treatment preoperatively
Number of subjects: 288
Study 3618133 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative treatment)
Number of subjects: 288
Study 3618133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases where CT was not detected
Number of subjects: 288
Study 29634491 — intervention group
Group type: COMPARATOR
Intervention: Interscalene block
Number of subjects: 189
Study 29634491 — intervention group
Group type: COMPARATOR
Intervention: Supraclavicular block
Number of subjects: 189
Study 29634491 — intervention group
Group type: COMPARATOR
Intervention: Anterior suprascapular block
Number of subjects: 189
Study 28577668 — intervention group
Group type: EXPERIMENTAL
Intervention: Model derived from ASCEND-HF trial cohort (n=4,767)
Number of subjects: 666
Study 28577668 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort (n=666)
Number of subjects: 666
Study 28577668 — intervention group
Group type: EXPERIMENTAL
Intervention: Final 10-variable clinical prediction model
Number of subjects: 666
Study 28577668 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding ischemic heart failure, troponin, and B-type natriuretic peptide
Number of subjects: 666
Study 26280823 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil (EVOO) 50 mL daily for 20 days
Number of subjects: 39
Study 26280823 — intervention group
Group type: COMPARATOR
Intervention: Refined Olive Oil (ROO) 50 mL daily for 20 days
Number of subjects: 39
Study 26280823 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil (EVOO)
Number of subjects: 39
Study 23766338 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) monotherapy 400/100 mg twice daily
Number of subjects: 105
Study 23766338 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) monotherapy
Number of subjects: 105
Study 23766338 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (zidovudine/lamivudine 300/150 mg twice daily)
Number of subjects: 105
Study 20638827 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-esterified triglycerides
Number of subjects: 72
Study 20638827 — intervention group
Group type: COMPARATOR
Intervention: Natural fish oil
Number of subjects: 72
Study 20638827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl esters
Number of subjects: 72
Study 20638827 — intervention group
Group type: EXPERIMENTAL
Intervention: Free fatty acids
Number of subjects: 72
Study 20638827 — intervention group
Group type: COMPARATOR
Intervention: Natural triglycerides
Number of subjects: 72
Study 18830521 — intervention group
Group type: EXPERIMENTAL
Intervention: Microspirometry
Number of subjects: 611
Study 19911247 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined general/epidural anesthesia (study group)
Number of subjects: 99
Study 19911247 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (control group)
Number of subjects: 99
Study 15877670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (125 mg of ferric gluconate per treatment)
Number of subjects: 19
Study 15877670 — intervention group
Group type: COMPARATOR
Intervention: Control (no iron administration)
Number of subjects: 19
Study 15877670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 19
Study 15877670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron and Control
Number of subjects: 19
Study 12145220 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg repaglinide
Number of subjects: 24
Study 12145220 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg glipizide
Number of subjects: 24